Solventum Corporation (NYSE:SOLV) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Solventum Corporation (NYSE:SOLV) have been given an average rating of “Moderate Buy” by the fourteen research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $84.25.

Several analysts have weighed in on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Wedbush assumed coverage on shares of Solventum in a research note on Friday, May 15th. They issued an “outperform” rating and a $94.00 target price for the company. Wall Street Zen downgraded Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. KeyCorp increased their price target on Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, Wells Fargo & Company dropped their price target on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a report on Wednesday, May 6th.

Solventum Stock Up 0.1%

SOLV opened at $76.92 on Monday. The firm’s 50-day simple moving average is $68.68 and its 200-day simple moving average is $74.82. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. Solventum has a twelve month low of $62.38 and a twelve month high of $88.20. The firm has a market cap of $13.32 billion, a price-to-earnings ratio of 9.43, a PEG ratio of 1.19 and a beta of 0.59.

Solventum (NYSE:SOLV) last announced its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter last year, the company posted $1.34 EPS. The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Equities research analysts anticipate that Solventum will post 6.57 EPS for the current fiscal year.

Insider Activity at Solventum

In other Solventum news, Director Amy Mcbride Wendell bought 1,475 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were bought at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the acquisition, the director owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.24% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Hilltop National Bank increased its position in Solventum by 71.3% in the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after acquiring an additional 129 shares in the last quarter. CrossGen Wealth LLC acquired a new position in shares of Solventum during the fourth quarter worth approximately $25,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Solventum during the third quarter worth approximately $25,000. Clearstead Trust LLC grew its stake in shares of Solventum by 61.0% during the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after purchasing an additional 150 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators grew its stake in shares of Solventum by 78.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock valued at $27,000 after purchasing an additional 163 shares during the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.